6 Results for "

DLL3 ADC

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "DLL3 ADC" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99043
CAS No.: 1613313-01-1
Synonyms: SC-0001

Target:  

Notch

Research Areas:  

Cancer

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
loading...
    loading...
Cat. No.: HY-164729
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
loading...
    loading...
Cat. No.: HY-132257
CAS No.: 1613313-09-9
Synonyms: SC-002
Research Areas:  

Cancer

Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .
loading...
    loading...
Cat. No.: HY-159072
CAS No.: 2575682-08-3
Purity:  96.22%
Research Areas:  

Cancer

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
loading...
    loading...
Cat. No.: HY-P990896

Target:  

ADC Antibodies

Research Areas:  

Cancer

FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
loading...
    loading...
Cat. No.: HY-P992148
CAS No.: 3058592-86-9
Synonyms: ZL-1310 Antibody

Target:  

Notch

Research Areas:  

Cancer

Zocilurtatug is a human monoclonal antibody against DLL3. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...